Anuncio
Mercados españoles cerrados

  • S&P 500

    5.317,45
    +14,18 (+0,27%)
     

  • Nasdaq

    16.787,56
    +101,59 (+0,61%)
     

  • NIKKEI 225

    39.069,68
    +282,30 (+0,73%)
     

  • Dólar/Euro

    1,0867
    -0,0005 (-0,04%)
     

  • Petróleo Brent

    83,55
    -0,43 (-0,51%)
     

  • Bitcoin EUR

    62.374,95
    +918,33 (+1,49%)
     

  • CMC Crypto 200

    1.379,18
    +24,76 (+1,83%)
     

  • Oro

    2.428,80
    +11,40 (+0,47%)
     

  • HANG SENG

    19.636,22
    +82,61 (+0,42%)
     

  • Petróleo WTI

    79,67
    -0,39 (-0,49%)
     

  • EUR/GBP

    0,8544
    -0,0015 (-0,17%)
     

  • Plata

    32,17
    +0,92 (+2,93%)
     

  • IBEX 35

    11.339,50
    +11,80 (+0,10%)
     

  • FTSE 100

    8.424,20
    +3,94 (+0,05%)
     

Here's What Key Metrics Tell Us About Insulet (PODD) Q1 Earnings

Zacks Equity Research
·2 min de lectura

Insulet (PODD) reported $441.7 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 23.4%. EPS of $0.73 for the same period compares to $0.23 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $423.52 million, representing a surprise of +4.29%. The company delivered an EPS surprise of +87.18%, with the consensus EPS estimate being $0.39.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ANUNCIO

Here is how Insulet performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- International Omnipod: $115.30 million compared to the $106.32 million average estimate based on six analysts. The reported number represents a change of +16.9% year over year.

  • Revenue- U.S. Omnipod: $317.70 million versus $311.93 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +22.7% change.

  • Revenue- Total Omnipod: $433 million compared to the $418.25 million average estimate based on six analysts. The reported number represents a change of +21.1% year over year.

  • Revenue- Drug Delivery: $8.70 million versus $5.56 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +1640% change.

View all Key Company Metrics for Insulet here>>>

Shares of Insulet have returned -1% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Insulet Corporation (PODD) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research